EPZM | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (221)

View All

Latest Posts

About This Stock More About This Stock
Notable Insider Buys: Continental Resources, Fox, Groupon And More
Article By: Benzinga
Saturday, June 27, 2020 7:24 PM EDT
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. So insider buying can be an encouraging signal for potential investors.
In this article: CLR, ED, CATM, RPRX, GRPN, WSBC, EPZM, FOX, VST
Read
The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke, And Ultragenyx
Article By: Benzinga
Sunday, June 14, 2020 3:13 PM EDT
Biotech stocks came under pressure along with the broader market in the week that ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-board sell-off in the global markets.
In this article: MRK, EVOK, RARE, EPZM Also: AZN, GILD, BMY, SNY, RPRX, CELG, PRQR, NBRV, CBIO, UROV, CNTG
Read
Wall Street's Top Weekend Stories, Sunday Dec. 6th
Article By: The Fly
Sunday, January 6, 2019 9:10 PM EDT
Stocks rebounded following a positive jobs report, Powell's comments, and more.
In this article: AZN, GME, MAR, FTNT, IRWD, INTC, NFLX, EPZM
Read
Epizyme Announces Closing Of Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire
Tuesday, September 19, 2017 10:19 AM EDT
Epizyme, Inc., today announced the closing of its public offering of 10,557,000 shares of its common stock at a price of $15.25 per share, before underwriting discounts.
In this article: EPZM
Read
Epizyme Announces Pricing Of Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire
Thursday, September 14, 2017 1:24 PM EDT
Epizyme, Inc., today announced the pricing of an underwritten public offering of 9,180,000 shares of its common stock at a price of $15.25 per share, before underwriting discounts.
In this article: EPZM
Read
All Posts

Latest Tweets for $EPZM

No tweets yet!

PARTNER HEADLINES